Review: cellular senescence and organismal aging as distinct but linked processes
This review abstract distinguishes aging, the progressive decline of physiological function at the organismal level, from cellular senescence, a stable cell-cycle arrest triggered by stress. It discusses shared mechanisms, biomarkers, senolytics and partial reprogramming, and how senescent cells may contribute to age-related decline. [1]
Automatic summary · not editorially reviewed
The key findings
The review abstract says aging and cellular senescence are biologically distinct but interconnected and often used interchangeably. [1]
Aging is described as progressive decline in physiological integrity and function at the organismal level; cellular senescence as a stable cell-cycle arrest triggered by stress. [1]
The abstract emphasizes that accumulation of senescent cells contributes to age-related functional decline and discusses senolytics and partial reprogramming as emerging strategies. [1]
The source at a glance
- Study type / format
- Review (abstract only)
- Population / context
- Not specified; the abstract concerns aging research generally, not a defined group of people or animals.
- Summary based on
- Study abstract
- Original publication
- July 13, 2026
Aging versus cellular senescence in the review
The abstract states that aging and cellular senescence are biologically distinct but interconnected, yet are often used interchangeably in biomedical research and theory. Aging is described as the progressive decline in physiological integrity and function at the organismal level. Cellular senescence is described as a stable cell-cycle arrest triggered by stress such as DNA damage, telomere shortening, epigenetic dysregulation and mitochondrial dysfunction. The review says it dissects the molecular basis of both and highlights differences, mechanistic overlaps and roles in health and disease.
Supporting source [1]
Senescent cells and age-related decline in the review
The abstract places particular emphasis on how the accumulation of senescent cells actively contributes to age-related functional decline. It also mentions emerging biomarkers and therapeutic strategies such as senolytics and partial reprogramming. As possible future interventions for age-related disorders it names therapies targeting specific components of the senescence-associated secretory phenotype or selectively modulating senescent cell burden. These are described as prospects, not as established treatments.
Supporting source [1]
Abstract-only scope of this review summary
The supplied text is the abstract of a review, so no individual studies, participants, follow-up periods or effect sizes are reported here. Statements about senescent cells contributing to decline and about senolytics or partial reprogramming are framed as review discussion and future directions. The abstract does not establish that any of these strategies prevents disease or extends human lifespan. The full text was not reviewed.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. No study design, sample, follow-up or effect sizes are reported, and the therapeutic strategies are presented as emerging prospects rather than established benefits.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Piritore FC, Braggio M, Minoia A, Bolognin S, Cominacini M, Trabetti E, Bombieri C, Romanelli MG, Dalle Carbonare L, Valenti MT. · europepmc.org · July 13, 2026